# Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

> **NCT00556348** · PHASE4 · COMPLETED · sponsor: **Instituto de Olhos de Goiania** · enrollment: 500 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00556348
- **Lead sponsor:** Instituto de Olhos de Goiania
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-10
- **Final completion:** 2008-11
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2011-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556348, "Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00556348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*